Treating Acute Leukemias in
Japan and the Asia-Pacific Region
Bridging Science and Practice: From Newest Clinical Approaches to Real-World Clinical Cases
Overview
This 2-day virtual program offers a comprehensive overview of the latest clinical updates and novel treatment strategies for acute leukemia, presented by experts. Attendees will have the opportunity to gain knowledge on optimal treatment of leukemia patients, join patient case-based discussions, and interact with experts.
Date and Location
September 10–11, 2023; Webinar
Co-Chairs
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Naval Daver, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty
Daniel J. DeAngelo, MD, PhD
Harvard Medical School, Boston, MA, USA
Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Shaun Fleming, MBBS(Hons), FRACP, FRCPA
Melbourne Haematology, Richmond, VIC, Australia
Agenda
This 2-day interactive virtual meeting with global experts will focus on the treatment of patients with acute leukemia in various countries within the Asia-Pacific region.
Day 1: Follow interactive presentations and case-based discussions on the latest updates for ALL and AML prognosis and management, including the role of MRD, risk stratification, and long-term safety considerations, and engage with the faculty in panel discussions on optimal treatment, patient access, and regional challenges across the Asia-Pacific region.
Day 2: Join to learn more about current approaches for relapsed ALL and AML, considerations for AYA ALL management (including case-based discussions), and the evolving role of transplantation, and interact with faculty during a panel discussion on how first-line therapy influences subsequent treatment.
Day 1 – PLENARY SESSIONS
Sunday, September 10, 2023
8.00 AM – 11.00 AM (UTC +8) Shanghai
9.00 AM – 12.00 PM (UTC +9) Tokyo
10.00 AM – 1.00 PM (UTC +10) Sydney
| Time (UTC +8) | Topic | Presenter |
| 8.00 AM – 8.10 AM |
Welcome and meeting overview | Elias Jabbour |
| 8.10 AM – 8.25 AM |
Review of prognostic value of MRD in ALL and AML | Jae Park |
| 8.25 AM – 8.40 AM |
Latest achievements and developments in ALL and AML | Elias Jabbour |
| 8.40 AM – 8.55 AM |
Genetic characterization and risk stratification of AML | Daniel DeAngelo |
| 8.55 AM – 9.25 AM |
ALL case-based panel discussion
|
Elias Jabbour and all faculty |
| 9.25 AM – 9.35 AM |
Break | |
| 9.35 AM – 9.50 AM |
Therapeutic approaches in high-risk and frail AML patients | Naval Daver |
| 9.50 AM – 10.05 AM |
Current approach to maintenance strategies in ALL and AML | Jae Park |
| 10.05 AM – 10.20 AM |
Long-term safety considerations in AML | Shaun Fleming |
| 10.20 AM – 10.50 AM |
Panel discussion: Open questions in ALL and AML – regional specificities | Elias Jabbour and all faculty |
| 10.50 AM – 11.00 AM |
Session close | Elias Jabbour |
Day 2 – Plenary Sessions
Monday, September 11, 2023
8.00 AM – 11.00 AM (UTC +8) Shanghai
9.00 AM – 12.00 PM (UTC +9) Tokyo
10.00 AM – 1.00 PM (UTC +10) Sydney
| Time (UTC +8) | Topic | Presenter |
| 8.00 AM – 8.10 AM |
Welcome to Day 2 | Elias Jabbour |
| 8.10 AM – 8.30 AM |
Current treatment options for relapsed ALL in adult and elderly patients | Elias Jabbour |
| 8.30 AM – 8.50 AM |
Current treatment options for relapsed AML in adult and elderly patients | Junichuro Yuda |
| 8.50 AM – 9.20 AM |
Case-based panel discussion
|
Naval Daver and all faculty |
| 9.20 AM – 9.30 AM |
Break | |
| 9.30 AM – 9.50 AM |
AYA ALL patients: What is the current treatment approach for this diverse patient population? Special considerations for adolescents and young adults and how we can use this experience in adult patients | Daniel DeAngelo |
| 9.50 AM – 10.20 AM |
Current and future role of transplantation in acute leukemias
|
Jae Park/Shaun Fleming |
| 10.20 AM – 10.50 AM |
Panel discussion: How treatment in first line influences further approaches in ALL and AML
|
Elias Jabbour and all faculty |
| 10.50 AM – 11.00 AM |
Session close | Elias Jabbour |
